Elanix Biotechnologies AG

M&A Activity • Sep 30, 2016

News Details

Ad-hoc | 30 September 2016 19:17

ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

Elanix Biotechnologies AG / Key word(s): Takeover

30.09.2016 19:17

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

Nyon, Switzerland and Potsdam, Germany, September 30, 2016 -- Elanix
Biotechnologies AG ("Elanix" - FSE: ELN), a developer of tissue
regeneration products, announced today that Elanix-Technologies SA in Nyon,
Switzerland (a 100% subsidiary of Elanix Biotechnologies AG, Potsdam)
entered into a purchase agreement to acquire 100% of equity of Repair-A SA,
a Lausanne based pharma and cosmetic company. It has been agreed not to
disclose the sum involved.

Repair-A SA is owner of two medical cosmetic products to alleviate
dermatological and gynecological conditions. Elanix already has an
exclusivity to sell both products in CH and EU, with this acquisition
Elanix will be able to fully control the product formulation, production
and commercialization world-wide. Elanix anticipates significant sales
growth in the coming months through combination of direct and distributor
sales in Switzerland, Europe and beyond.

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue
regeneration products for acute wound care, dermatological and
gynecological applications, and provides services in cell technologies. The
company was founded in 2013 as a spin-out from the University Hospital of
Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell
technology. Progenitor cells are fully differentiated yet immunologically
neutral cells that are very potent inducers of tissue growth and healing.
Elanix owns GMP certified Master and Working cell banks with vast
quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland with offices in Potsdam
and listed on the Frankfurt stock exchange under the symbol ELN. For more
information and updates, visit www.elanix-biotechnologies.com.

Press Contact:

Elanix Biotechnologies AG
investor.relations@elanix.ch

Disclaimer / Forward-looking statements:

This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Elanix Biotechnologies AG. This
announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any person
in the United States of America (the "United States"), Australia, Canada or
Japan or in any jurisdiction to whom or in which such offer or solicitation
is unlawful. The securities referred to in this announcement will not be
and have not been registered under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act") and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration requirements under the U.S. Securities Act. Subject to certain
exceptions, the securities referred to in this announcement may not be
offered or sold in Australia, Canada or Japan, or to, or for the account or
benefit of, any national, resident or citizen of Australia, Canada or
Japan. The offer and sale of the securities referred to in this
announcement has not been and will not be registered under the U.S.
Securities Act or under the applicable securities laws of Australia, Canada
or Japan. There will be no public offer of the securities in the United
States.

This publication may contain certain forward-looking statements concerning
the Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the Company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision.
The Company disclaims any obligation to update these forward-looking
statements.

30.09.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language: English
Company: Elanix Biotechnologies AG
c/o Rechtsanwalt Hr. Torsten Cejka, Domstrasse 22
14482 Potsdam
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated
Unofficial Market in Berlin, Dusseldorf

End of Announcement DGAP News-Service

---